United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/553,906	10/21/2005	Tomas Bergman	71752-81710	1877
26288 7590 11/29/2007 ALBIHNS STOCKHOLM AB			EXAMINER	
BOX 5581, LINNEGATAN 2			WALICKA, MALGORZATA A	
SE-114 85 ST STOCKHOLN	OCKHOLM; SWEDENn		ART UNIT	PAPER NUMBER
SWEDEN		,	1652	
			MAIL DATE	DELIVERY MODE
			11/29/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
ć.	10/553,906	BERGMAN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Malgorzata A. Walicka	1652				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONED	I. ely filed the mailing date of this communication. O (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 2a) This action is FINAL . 2b) This 3) Since this application is in condition for allowan closed in accordance with the practice under E.	- action is non-final. ice except for formal matters, pro					
Disposition of Claims						
4) ⊠ Claim(s) 1-20 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) 1-20 are subject to restriction and/or e	·					
Application Papers						
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the consequence of the conseque	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is objected to be a second to be a secon	37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:	te				

10/553,906 Art Unit: 1652

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-9, 11-12, 13-14, 16-17, 18-20, drawn to alkaline sphingomyelinase of SEQ ID NO: 1 and 4, their variants, encoding DNA molecules, vectors, host cells, and a method of recombinant production of the enzymes.

Group II, claim(s) 10 drawn to method for isolation of human Alk-Smase protein from human small intestin or colon.

Group III, claim(s) 15 in part, drawn to a method for treating colon cancer comprising administering a composition comprising Alk-Smase of SEQ ID NO: 1 or SEQ ID NO: 4 or their variants.

Group IV, claim(s) 15 in part, drawn to a method for treating colon cancer comprising administering a composition comprising a DNA encoding protein of SEQ ID NO: 1 or SEQ ID NO: 4 and their variants.

Application/Control Number:

10/553,906 Art Unit: 1652

Regarding Group I, it is directed to at least two products and one method of use sad products, wherein said products that meet the same or similar technical feature. Regarding Groups II-IV, they are directed to three methods different than the method incorporated in Group I. 37 CFR 1.475 does not provide for multiple products or methods within a single application, therefore, unity of invention is lacking with regard to Group II-IV and between all the indicated groups.

For the reason indicated above the restriction is proper.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Malgorzata A. Walicka whose telephone number is (571) 272-0944. The examiner can normally be reached on Monday-Friday from 10:00 a.m. to 4:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, can be reached on (571) 272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Malgorzata A. Walicka, Ph.D.

Art Unit 1652

Patent Examiner

TECHNOLOGY OFFICE 1979